Details
| Stereochemistry | ABSOLUTE |
| Molecular Formula | C28H37ClO7 |
| Molecular Weight | 521.042 |
| Optical Activity | UNSPECIFIED |
| Defined Stereocenters | 8 / 8 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
[H][C@@]12C[C@H](C)[C@](OC(=O)CC)(C(=O)COC(=O)CC)[C@@]1(C)C[C@H](O)[C@@]3(Cl)[C@@]2([H])CCC4=CC(=O)C=C[C@]34C
InChI
InChIKey=KUVIULQEHSCUHY-XYWKZLDCSA-N
InChI=1S/C28H37ClO7/c1-6-23(33)35-15-22(32)28(36-24(34)7-2)16(3)12-20-19-9-8-17-13-18(30)10-11-25(17,4)27(19,29)21(31)14-26(20,28)5/h10-11,13,16,19-21,31H,6-9,12,14-15H2,1-5H3/t16-,19-,20-,21-,25-,26-,27-,28-/m0/s1
Approval Year
Cmax
| Value | Dose | Co-administered | Analyte | Population |
|---|---|---|---|---|
1.419 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/12107606/ |
100 μg 4 times / day multiple, respiratory dose: 100 μg route of administration: Respiratory experiment type: MULTIPLE co-administered: |
BECLOMETHASONE 17-MONOPROPIONATE plasma | Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN |
AUC
| Value | Dose | Co-administered | Analyte | Population |
|---|---|---|---|---|
4.985 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/12107606/ |
100 μg 4 times / day multiple, respiratory dose: 100 μg route of administration: Respiratory experiment type: MULTIPLE co-administered: |
BECLOMETHASONE 17-MONOPROPIONATE plasma | Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN |
T1/2
| Value | Dose | Co-administered | Analyte | Population |
|---|---|---|---|---|
2.8 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/12107606/ |
100 μg 4 times / day multiple, respiratory dose: 100 μg route of administration: Respiratory experiment type: MULTIPLE co-administered: |
BECLOMETHASONE 17-MONOPROPIONATE plasma | Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN |
Doses
| Dose | Population | Adverse events |
|---|---|---|
320 ug 1 times / day steady, intranasal Recommended Dose: 320 ug, 1 times / day Route: intranasal Route: steady Dose: 320 ug, 1 times / day Sources: Page: page 114 |
unhealthy, 12-74 years n = 414 Health Status: unhealthy Condition: allergic rhinitis Age Group: 12-74 years Sex: M+F Population Size: 414 Sources: Page: page 114 |
Disc. AE: Epistaxis, Increased intraocular pressure... AEs leading to discontinuation/dose reduction: Epistaxis (5 patients) Sources: Page: page 114Increased intraocular pressure (1 patient) Colon cancer (2 patients) Nasal septum ulceration (2 patients) Nasal discomfort (2 patients) Sinusitis (2 patients) Nasal congestion (1 patient) Headache (1 patient) Nasal mucosal disorder (1 patient) |
320 ug 1 times / day steady, intranasal Recommended Dose: 320 ug, 1 times / day Route: intranasal Route: steady Dose: 320 ug, 1 times / day Sources: Page: page 114 |
unhealthy, 12-82 years n = 935 Health Status: unhealthy Condition: allergic rhinitis Age Group: 12-82 years Sex: M+F Population Size: 935 Sources: Page: page 114 |
Disc. AE: Sinusitis, Nasopharyngitis... AEs leading to discontinuation/dose reduction: Sinusitis Sources: Page: page 114Nasopharyngitis Nasal congestion Headache Infection respiratory |
AEs
| AE | Significance | Dose | Population |
|---|---|---|---|
| Headache | 1 patient Disc. AE |
320 ug 1 times / day steady, intranasal Recommended Dose: 320 ug, 1 times / day Route: intranasal Route: steady Dose: 320 ug, 1 times / day Sources: Page: page 114 |
unhealthy, 12-74 years n = 414 Health Status: unhealthy Condition: allergic rhinitis Age Group: 12-74 years Sex: M+F Population Size: 414 Sources: Page: page 114 |
| Increased intraocular pressure | 1 patient Disc. AE |
320 ug 1 times / day steady, intranasal Recommended Dose: 320 ug, 1 times / day Route: intranasal Route: steady Dose: 320 ug, 1 times / day Sources: Page: page 114 |
unhealthy, 12-74 years n = 414 Health Status: unhealthy Condition: allergic rhinitis Age Group: 12-74 years Sex: M+F Population Size: 414 Sources: Page: page 114 |
| Nasal congestion | 1 patient Disc. AE |
320 ug 1 times / day steady, intranasal Recommended Dose: 320 ug, 1 times / day Route: intranasal Route: steady Dose: 320 ug, 1 times / day Sources: Page: page 114 |
unhealthy, 12-74 years n = 414 Health Status: unhealthy Condition: allergic rhinitis Age Group: 12-74 years Sex: M+F Population Size: 414 Sources: Page: page 114 |
| Nasal mucosal disorder | 1 patient Disc. AE |
320 ug 1 times / day steady, intranasal Recommended Dose: 320 ug, 1 times / day Route: intranasal Route: steady Dose: 320 ug, 1 times / day Sources: Page: page 114 |
unhealthy, 12-74 years n = 414 Health Status: unhealthy Condition: allergic rhinitis Age Group: 12-74 years Sex: M+F Population Size: 414 Sources: Page: page 114 |
| Colon cancer | 2 patients Disc. AE |
320 ug 1 times / day steady, intranasal Recommended Dose: 320 ug, 1 times / day Route: intranasal Route: steady Dose: 320 ug, 1 times / day Sources: Page: page 114 |
unhealthy, 12-74 years n = 414 Health Status: unhealthy Condition: allergic rhinitis Age Group: 12-74 years Sex: M+F Population Size: 414 Sources: Page: page 114 |
| Nasal discomfort | 2 patients Disc. AE |
320 ug 1 times / day steady, intranasal Recommended Dose: 320 ug, 1 times / day Route: intranasal Route: steady Dose: 320 ug, 1 times / day Sources: Page: page 114 |
unhealthy, 12-74 years n = 414 Health Status: unhealthy Condition: allergic rhinitis Age Group: 12-74 years Sex: M+F Population Size: 414 Sources: Page: page 114 |
| Nasal septum ulceration | 2 patients Disc. AE |
320 ug 1 times / day steady, intranasal Recommended Dose: 320 ug, 1 times / day Route: intranasal Route: steady Dose: 320 ug, 1 times / day Sources: Page: page 114 |
unhealthy, 12-74 years n = 414 Health Status: unhealthy Condition: allergic rhinitis Age Group: 12-74 years Sex: M+F Population Size: 414 Sources: Page: page 114 |
| Sinusitis | 2 patients Disc. AE |
320 ug 1 times / day steady, intranasal Recommended Dose: 320 ug, 1 times / day Route: intranasal Route: steady Dose: 320 ug, 1 times / day Sources: Page: page 114 |
unhealthy, 12-74 years n = 414 Health Status: unhealthy Condition: allergic rhinitis Age Group: 12-74 years Sex: M+F Population Size: 414 Sources: Page: page 114 |
| Epistaxis | 5 patients Disc. AE |
320 ug 1 times / day steady, intranasal Recommended Dose: 320 ug, 1 times / day Route: intranasal Route: steady Dose: 320 ug, 1 times / day Sources: Page: page 114 |
unhealthy, 12-74 years n = 414 Health Status: unhealthy Condition: allergic rhinitis Age Group: 12-74 years Sex: M+F Population Size: 414 Sources: Page: page 114 |
| Headache | Disc. AE | 320 ug 1 times / day steady, intranasal Recommended Dose: 320 ug, 1 times / day Route: intranasal Route: steady Dose: 320 ug, 1 times / day Sources: Page: page 114 |
unhealthy, 12-82 years n = 935 Health Status: unhealthy Condition: allergic rhinitis Age Group: 12-82 years Sex: M+F Population Size: 935 Sources: Page: page 114 |
| Infection respiratory | Disc. AE | 320 ug 1 times / day steady, intranasal Recommended Dose: 320 ug, 1 times / day Route: intranasal Route: steady Dose: 320 ug, 1 times / day Sources: Page: page 114 |
unhealthy, 12-82 years n = 935 Health Status: unhealthy Condition: allergic rhinitis Age Group: 12-82 years Sex: M+F Population Size: 935 Sources: Page: page 114 |
| Nasal congestion | Disc. AE | 320 ug 1 times / day steady, intranasal Recommended Dose: 320 ug, 1 times / day Route: intranasal Route: steady Dose: 320 ug, 1 times / day Sources: Page: page 114 |
unhealthy, 12-82 years n = 935 Health Status: unhealthy Condition: allergic rhinitis Age Group: 12-82 years Sex: M+F Population Size: 935 Sources: Page: page 114 |
| Nasopharyngitis | Disc. AE | 320 ug 1 times / day steady, intranasal Recommended Dose: 320 ug, 1 times / day Route: intranasal Route: steady Dose: 320 ug, 1 times / day Sources: Page: page 114 |
unhealthy, 12-82 years n = 935 Health Status: unhealthy Condition: allergic rhinitis Age Group: 12-82 years Sex: M+F Population Size: 935 Sources: Page: page 114 |
| Sinusitis | Disc. AE | 320 ug 1 times / day steady, intranasal Recommended Dose: 320 ug, 1 times / day Route: intranasal Route: steady Dose: 320 ug, 1 times / day Sources: Page: page 114 |
unhealthy, 12-82 years n = 935 Health Status: unhealthy Condition: allergic rhinitis Age Group: 12-82 years Sex: M+F Population Size: 935 Sources: Page: page 114 |
PubMed
| Title | Date | PubMed |
|---|---|---|
| Differential potency of beclomethasone esters in-vitro on human T-lymphocyte cytokine production and osteoblast activity. | 2000 Apr |
|
| Evaluation of glucocorticoid receptor function in COPD lung macrophages using beclomethasone-17-monopropionate. | 2013 |
|
| Metabolism of beclomethasone dipropionate by cytochrome P450 3A enzymes. | 2013 May |
Patents
| Name | Type | Language | ||
|---|---|---|---|---|
|
Official Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Code | English | ||
|
Brand Name | English | ||
|
Brand Name | English | ||
|
Code | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
| Classification Tree | Code System | Code | ||
|---|---|---|---|---|
|
FDA ORPHAN DRUG |
356311
Created by
admin on Fri Dec 15 15:10:45 GMT 2023 , Edited by admin on Fri Dec 15 15:10:45 GMT 2023
|
||
|
FDA ORPHAN DRUG |
111198
Created by
admin on Fri Dec 15 15:10:45 GMT 2023 , Edited by admin on Fri Dec 15 15:10:45 GMT 2023
|
||
|
NCI_THESAURUS |
C521
Created by
admin on Fri Dec 15 15:10:45 GMT 2023 , Edited by admin on Fri Dec 15 15:10:45 GMT 2023
|
||
|
FDA ORPHAN DRUG |
146501
Created by
admin on Fri Dec 15 15:10:45 GMT 2023 , Edited by admin on Fri Dec 15 15:10:45 GMT 2023
|
||
|
FDA ORPHAN DRUG |
144201
Created by
admin on Fri Dec 15 15:10:45 GMT 2023 , Edited by admin on Fri Dec 15 15:10:45 GMT 2023
|
||
|
FDA ORPHAN DRUG |
285609
Created by
admin on Fri Dec 15 15:10:45 GMT 2023 , Edited by admin on Fri Dec 15 15:10:45 GMT 2023
|
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
100000091556
Created by
admin on Fri Dec 15 15:10:45 GMT 2023 , Edited by admin on Fri Dec 15 15:10:45 GMT 2023
|
PRIMARY | |||
|
3002
Created by
admin on Fri Dec 15 15:10:45 GMT 2023 , Edited by admin on Fri Dec 15 15:10:45 GMT 2023
|
PRIMARY | |||
|
1048506
Created by
admin on Fri Dec 15 15:10:45 GMT 2023 , Edited by admin on Fri Dec 15 15:10:45 GMT 2023
|
PRIMARY | |||
|
5B307S63B2
Created by
admin on Fri Dec 15 15:10:45 GMT 2023 , Edited by admin on Fri Dec 15 15:10:45 GMT 2023
|
PRIMARY | |||
|
294
Created by
admin on Fri Dec 15 15:10:45 GMT 2023 , Edited by admin on Fri Dec 15 15:10:45 GMT 2023
|
PRIMARY | |||
|
BECLOMETHASONE DIPROPIONATE
Created by
admin on Fri Dec 15 15:10:45 GMT 2023 , Edited by admin on Fri Dec 15 15:10:45 GMT 2023
|
PRIMARY | Description: A white to creamy white powder; odourless. Solubility: Practically insoluble in water; soluble in 60 parts of ethanol (~750 g/l) TS. Category: Antiasthmatic drug. Storage: Beclometasone dipropionate should be kept in a well-closed container, protected from light. Definition: Beclometasone dipropionate contains not less than 96.0% and not more than 104.0% of C28H37ClO7, calculated with reference to the dried substance. | ||
|
DB00394
Created by
admin on Fri Dec 15 15:10:45 GMT 2023 , Edited by admin on Fri Dec 15 15:10:45 GMT 2023
|
PRIMARY | |||
|
SUB00681MIG
Created by
admin on Fri Dec 15 15:10:45 GMT 2023 , Edited by admin on Fri Dec 15 15:10:45 GMT 2023
|
PRIMARY | |||
|
1348
Created by
admin on Fri Dec 15 15:10:45 GMT 2023 , Edited by admin on Fri Dec 15 15:10:45 GMT 2023
|
PRIMARY | RxNorm | ||
|
5894
Created by
admin on Fri Dec 15 15:10:45 GMT 2023 , Edited by admin on Fri Dec 15 15:10:45 GMT 2023
|
PRIMARY | |||
|
5B307S63B2
Created by
admin on Fri Dec 15 15:10:45 GMT 2023 , Edited by admin on Fri Dec 15 15:10:45 GMT 2023
|
PRIMARY | |||
|
755901
Created by
admin on Fri Dec 15 15:10:45 GMT 2023 , Edited by admin on Fri Dec 15 15:10:45 GMT 2023
|
PRIMARY | |||
|
CHEMBL1200500
Created by
admin on Fri Dec 15 15:10:45 GMT 2023 , Edited by admin on Fri Dec 15 15:10:45 GMT 2023
|
PRIMARY | |||
|
226-886-0
Created by
admin on Fri Dec 15 15:10:45 GMT 2023 , Edited by admin on Fri Dec 15 15:10:45 GMT 2023
|
PRIMARY | |||
|
DTXSID3048730
Created by
admin on Fri Dec 15 15:10:45 GMT 2023 , Edited by admin on Fri Dec 15 15:10:45 GMT 2023
|
PRIMARY | |||
|
BECLOMETASONE DIPROPIONATE
Created by
admin on Fri Dec 15 15:10:45 GMT 2023 , Edited by admin on Fri Dec 15 15:10:45 GMT 2023
|
PRIMARY | |||
|
C299
Created by
admin on Fri Dec 15 15:10:45 GMT 2023 , Edited by admin on Fri Dec 15 15:10:45 GMT 2023
|
PRIMARY | |||
|
SUB26515
Created by
admin on Fri Dec 15 15:10:45 GMT 2023 , Edited by admin on Fri Dec 15 15:10:45 GMT 2023
|
PRIMARY | |||
|
5534-09-8
Created by
admin on Fri Dec 15 15:10:45 GMT 2023 , Edited by admin on Fri Dec 15 15:10:45 GMT 2023
|
PRIMARY | |||
|
21700
Created by
admin on Fri Dec 15 15:10:45 GMT 2023 , Edited by admin on Fri Dec 15 15:10:45 GMT 2023
|
PRIMARY | |||
|
m2287
Created by
admin on Fri Dec 15 15:10:45 GMT 2023 , Edited by admin on Fri Dec 15 15:10:45 GMT 2023
|
PRIMARY | Merck Index |
ACTIVE MOIETY
METABOLITE INACTIVE (PARENT)
METABOLITE LESS ACTIVE (PARENT)
SALT/SOLVATE (PARENT)
SUBSTANCE RECORD
